Journal of Medicinal Chemistry

Letter

Subscriber access provided by American Chemical Society

Design and Synthesis of Tricyclic Imidazo[4,5-*b*]pyridin-2-ones as Corticotropin-Releasing Factor-1 Antagonists

Zhiqiang Guo, John E. Tellew, Raymond S. Gross, Brian Dyck, Jonathan Grey, Mustapha Haddach, Mehrak Kiankarimi, Marion Lanier, Bin-Feng Li, Zhiyong Luo, James R. McCarthy, Manisha Moorjani, John Saunders, Robert Sullivan, Xiaohu Zhang, Said Zamani-Kord, Dimitri E. Grigoriadis, Paul D. Crowe, Ta Kung Chen, and John P. Williams *J. Med. Chem.*, 2005, 48 (16), 5104-5107• DOI: 10.1021/jm050384+ • Publication Date (Web): 09 July 2005
Downloaded from http://pubs.acs.org on March 28, 2009

More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

View the Full Text HTML



Design and Synthesis of Tricyclic Imidazo[4,5-*b*]pyridin-2-ones as Corticotropin-Releasing Factor-1 Antagonists

Zhiqiang Guo,^{*,†} John E. Tellew,[†] Raymond S. Gross,[†] Brian Dyck,[†] Jonathan Grey,[†] Mustapha Haddach,[†] Mehrak Kiankarimi,[†] Marion Lanier,[†] Bin-Feng Li,[†] Zhiyong Luo,[†] James R. McCarthy,[†] Manisha Moorjani,[†] John Saunders,[†] Robert Sullivan,[†] Xiaohu Zhang,[†] Said Zamani-Kord,[†] Dimitri E. Grigoriadis,[‡] Paul D. Crowe,[‡] Ta Kung Chen,[§] and John P. Williams[†]

Departments of Medicinal Chemistry, Pharmacology, and Preclinical Development, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, California 92130


Received April 22, 2005

Abstract: The synthesis and SAR studies of tricyclic imidazo-[4,5-*b*]pyridin-2-ones as human corticotropin-releasing factor receptor (CRF₁) antagonists are discussed herein. Compound **16g** was identified as a functional antagonist that inhibited CRF-stimulated cyclic adenosine monophosphate production and CRF-induced adrenocorticotrophic hormone release. Pharmacokinetics studies in rats showed that **16g** was orally bioavailable, had good brain penetration, and had a moderate half-life. In our effort to identify CRF₁ antagonists with improved pharmacokinetics properties, **16g** exhibited a favorably lower volume of distribution.

Corticotropin-releasing factor (CRF, also known as corticotropin-releasing hormone), a 41 amino acid neuropeptide isolated from mammalian brain, is the prime regulator of the hypothalamic-pituitary-adrenal (HPA) stress response.¹ CRF mediates its actions through highaffinity binding to its receptors, CRF1 and CRF2, both of which are members of the class B subfamily of G-protein-coupled receptors. Prolonged activation of the central CRF system may play a fundamental role in the etiology of major depression.² Hypersecretion of hypothalamic CRF manifests itself in a down-regulation of CRF receptors in the anterior pituitary as demonstrated by the blunted adrenocorticotrophic hormone (ACTH) response to peripherally administered CRF in severely depressed patients. Because of the key role that CRF plays in stress response, centrally acting CRF₁ antagonists are expected to have utility in treatment of stressrelated psychiatric disorders such as anxiety and depression.³

Many non-peptide CRF_1 antagonists from different chemical classes have been reported in recent years, and several representative examples are illustrated in Figure 1. Potent CRF_1 antagonists such as 1 (CP-154,526),⁴ 2 (antalarmin),⁵ 3 (NBI-27914),⁶ and 4 (DMP696)⁷ have been widely studied in many different animal models of CRF-related behavior. Although these compounds possess excellent in vitro activities as CRF_1 antagonists,

^{*} To whom correspondence should be addressed. Phone: 1-858-617-7657. Fax: 1-858-617-7619. E-mail: zguo@neurocrine.com. † Department of Medicinal Chemistry.



[§] Department of Preclinical Development.




Figure 1. Some small-molecule CRF₁ receptor antagonists.





Figure 2. Design of tricyclic CRF₁ receptor antagonists.

and several of them exhibited in vivo efficacy in the anxiety models when dosed orally, most of these compounds reported earlier suffer from high lipophilicity and poor water solubility.⁸ For example, **1** has a very long half-life (51 h) and high volume of distribution (105 L/kg) in rats.⁹ More recent efforts on the discovery of more hydrophilic CRF₁ antagonists generated **5** (NBI-30775/R121919),¹⁰ which has antidepressant efficacy in an open label phase IIA clinical trial in major depressive disorder patients.

Compounds 1–5 are based on monocyclic or bicyclic cores. We envisioned that synthesizing compounds with a third ring on the core structure would restrict the conformational freedom of their flexible "top region" (Figure 2) and thus would result in compounds that would populate a smaller subset of the biologically relevant conformations required for optimal biological activity. We recently reported on a series of conformationally constrained tricyclic pyrazolo[4,3-b]pyridines such as 6, which was found to be a potent functional antagonist of CRF₁.¹¹ In our effort to prepare potent CRF₁ antagonists with reduced lipophilicity, we have made tricyclic analogues of the polar 1,3-dihydroimidazo[4,5-b]pyridin-2-one series¹² (Figure 2), and the initial SAR and pharmacokinetics profiles of representative compounds from this series of CRF₁ antagonists are reported herein.

For the synthesis of tricyclic analogues we employed two general methods. In the first method (Scheme 1), a substituted pyridine ring was prepared (13), followed by construction of the imidazolone ring (15), and finally closure of the tetrahydropyrazine ring. The starting material 2,4-dichloro-6-methyl-3-nitropyridine (9) was readily prepared from commercially available 4-hyScheme 1^a




^a Reagents and conditions: (a) POCl₃, ACN, 82 °C, 85%; (b) 4-aminoheptane, Et₃N, ACN, -10 °C, 40%; (c) PhSO₂Cl, Et₃N, DMAP, 60 °C, 91%; (d) 4-aminoheptane, TsOH, acetonitrile, 68 °C, 80%; (e) POCl₃, acetonitrile, DIPEA, 90 °C, 87%; (f) ArNH₂, ACN, 65 °C, 95%; (g) Na₂S₂O₄, THF/water, room temp, 91%; (h) triphosgene, NEt₃, 0 °C, 80%; or carbonyldiimidazole, NEt₃, DMF, 76%; (i) 1,2-dibromoethane, DMF, NaH, room temp, 30–80%.

droxy-6-methyl-3-nitro-2(1H)-pyridone (8) and POCl₃.¹² 9 was then treated with 4-aminoheptane in acetonitrile at -10 °C to give a 3:1 mixture of 10 and its regioisomer (10a). In an improved version of this method, 8 was selectively monosulfonylated with benzenesulfonyl chloride, and the resulting sulfonate intermediate 11 was directly treated with 4-aminoheptane. This one-pot procedure yielded 12 in 73% yield with no purification issues. Chlorination of 12, followed by reaction with substituted anilines at elevated temperatures (\sim 140 °C), afforded the condensation products 13. The 5-nitro group of 13 was reduced with sodium hydrosulfite to provide the corresponding diaminopyridines 14, which were cyclized with triphosgene to form the imidazolone ring. The third ring was installed by treatment of 15 with 1,2-dibromoethane using sodium hydride as base in DMF or sodium hydroxide as base under phasetransfer conditions.

With the above synthetic routes, the upper amino substituent \mathbb{R}^1 was fixed at the beginning of the synthesis. We developed an alternative approach (Scheme 2) to explore the SAR at this position while keeping the bottom Ar substituent constant. Dealkylation of $16g^{13}$ was carried out in neat concentrated sulfuric acid to yield the secondary amine 17a. Top region \mathbb{R}^1 groups were then installed via base-mediated alkylation of intermediate 17a to yield the final compounds 17b-e. Compounds 18a-c and 19a-c were also prepared according to the synthetic route in Scheme 1 with the 3-pentyl or 1-methoxy-2-butyl group as the top amino substituent.

The compounds thus synthesized were tested for binding affinity at the cloned human CRF_1 receptor

Scheme 2^a



^{*a*} Reagents and conditions: (a) concentrated H_2SO_4 , 65 °C, 50%; (b) R¹Br or R¹I, NaH or 'BuOK, DMF, 20–50 °C, 15–70%.

Table 1.	Binding Affinities of 16a-l to the Human	CRF_1
Receptor		

Compds	Ar	$K_{i}(\mathrm{nM})^{a}$
2		3.1
6		4.5
16a	cı ţcı	5.1
16b	Br, ≸−∕	1.1
16c	ş- Cı	12
16d	€ CF3	17
16e		460
16f	₩ ₩	920
16g	ş-<>-o	2
16h		44
16i		130
16j	₽ ₽ O	140
16k	}CI	23
161	₩ N O	60

^a Receptor binding was conducted as described previously. Data are the average of three or more independent determinations. Typical standard errors were less than 30%.

expressed in leukocyte tyrosine kinase cells with sauvagine as the radiolabeled ligand, and the K_i values were determined from dose-response curves using concentrations from 1 nM to 10 μ M as described.¹⁴

The binding activity data of substitutions at the bottom aryl region of the tricyclic imidazolone series are summarized in Table 1. The top amino substituent (R¹) was initially kept constant as 4-heptyl, since this substituent was potent in our other tricyclic series (i.e., **6**).¹¹ The SAR pattern that emerged was in part similar to that seen for other CRF₁ antagonist scaffolds in that 2,4-disubstituted aryl groups gave good potency, particularly with lipophilic and relatively small substituents (**16a**,**b**). Analogue **16a** with a 2,4-dichlorophenyl group demonstrated a potent K_i of 5.1 nM, while the slightly bigger 2-bromo-4-isopropyl analogue **16b** was to identify polar substituents to help offset the contribution of the amino substituent (R¹) to the overall lipo-

Table 2. Binding Affinities of 17b-e, 18a-c, and 19a-c to the Human CRF₁ Receptor



Compds	\mathbb{R}^1	Ar	$K_{i}(nM)^{a}$
16g	4-heptyl	∳-∕o	2
17b	isopropyl	∳-∕ó	> 10,000
17c	n-butyl	∳-∕ó	8,800
17d	3-pentyl	∳-∕ó	8
17e	1-MeO-2-butyl	}–√o	150
18a	3-pentyl	ş-∕Cı	58
18b	3-pentyl	€ CF3	170
18c	3-pentyl	₽ ₽ ₽	20
19a	1-MeO-2-butyl	ş-∕Cı	200
19b	1-MeO-2-butyl	Ş-∕⊂−CF3	190
19c	1-MeO-2-butyl	ş Ş Do	1,000

^{*a*} Receptor binding was conducted as described previously. Data are the average of three or more independent determinations. Typical standard errors were less than 30%.

philicity of the compounds. Even though removal of the 2-chloro substitution in 16a resulted in a 2-fold loss of potency (16c), it demonstrated that the 2-aryl substituent is not required for good activity in this series. Accordingly, a series of 4-monosubstituted aryl analogues (16d-g) were prepared to look for simple and less lipophilic groups as the bottom. Although a strong electron-withdrawing trifluoromethyl group at the 4-position was tolerated (16d, 17 nM), the polar, electronwithdrawing methylsulfone and carboethoxy substituents dramatically reduced the binding affinity as seen in 16e and 16f ($K_i = 465$ and 920 nM, respectively). Incorporation of a less lipophilic, electron-donating methoxy group at the different positions on the bottom phenyl ring suggested that the 4-position (16g, 2 nM) was preferred over the 2- or 3-position analogues in potency. Moreover, extending the 4-methoxy to 4-ethoxy led to a decrease in potency by 2 orders of magnitude. Incorporation of a substituted pyridine ring on the bottom (16k,l) lowered the lipophilicity further but provided less active analogues than the corresponding phenyl compounds.

Binding results from variation of the upper region amino substituent \mathbb{R}^1 are depicted in Table 2. In our attempt to reduce overall lipophilicity, we investigated smaller alkyl replacements for the 4-heptyl group of **16g**. From this study, it is clear that the top region nitrogen substituents of tricyclic **17** participitate in a key binding interaction with the CRF receptor. Alkyl substituents smaller than the isopropyl group resulted in a total loss of binding activity, while *n*-butyl analogue **17c** exhibited only very weak binding. The 3-pentyl analogue had very good affinity (**17d**, 8 nM), even though it was still about 4-fold less potent than **16g**. Insertion of an oxygen atom into the five-carbon chain of **17d** (as shown in **17e**) decreased affinity further.

Further studies were carried out to determine whether the SAR of the bottom aryl region would be different if the heptyl substituent of **16** was replaced by a smaller, less lipophilic group. Binding data for representative 3-pentyl compounds **18a,b** and methoxybutyl compounds **19a,b** are also presented in Table 2. The results in general paralleled those seen in the 4-heptyl series, and the uniformally lower affinity of these compounds served to confirm the requirement for a lipophilic upper amino substituent for optimal potency. Adding a 2-aryl substitution to reimburse the loss of affinity from the top region (as shown in **18c** and **19c**) failed to improve the binding affinity.

Compound **16g** was very weakly basic with a pK_a of 4.9, and it possessed moderate lipophilicity with a $\log P$ value of 4.5, which was comparable to the reported value¹⁰ for **5** (log P = 4.9). Even though the free base had limited solubility in water (0.34 mg/mL), its L-malic acid salt was readily soluble in 1 N HCl (38 mg/mL). This compound had essentially no affinity for the CRF₂ receptor expressed in Chinese hamster ovary (CHO) cells at 10 μ M.¹⁵ **16g** showed no significant binding at $10 \,\mu\text{M}$ to over 60 different receptors, ion channels, and transporters. As a consequence, 16g was further evaluated for functional CRF₁ antagonism in vitro and in vivo. Compound 16g dose-dependently inhibited CRFstimulated cyclic adenosine monophosphate (cAMP) production in CHO cells expressing the CRF₁ receptor¹⁶ with an IC_{50} of 71 nM, which was comparable to that of $\mathbf{5}$ (IC₅₀ = 50 nM). In a second functional assay, $\mathbf{16g}$ was also found to functionally antagonize CRF-stimulated ACTH release from rat primary anterior pituitary cell cultures.¹⁴ The result showed that 16g was a potent antagonist in this assay with an IC_{50} of 150 nM.

We further determined the pharmacokinetics profile of 16g in male Sprague-Dawley rats, following intravenous and oral administration at 10 mg/kg. After an iv injection, 16g had a high plasma clearance (CL = $53.4 \text{ mL} \min^{-1} \text{kg}^{-1}$) and a small volume of distribution $(V_d = 7.2 \text{ L/kg})$ in rats, which resulted in a terminal half-life of 1.6 h. After oral administration of 16g, the C_{\max} in plasma and brain occurred simultaneously at 1 h after dosing. The mean maximal concentrations (C_{\max}) in plasma and brain tissue via oral administration were 356 ng/mL and 1180 ng/g, respectively. Oral bioavailability was estimated to be 30%, and on the basis of the AUC (0-6 h) ratio, the brain tissue was exposed to approximately 280% of the plasma concentration of 16g at this dosage. 16g had a notably smaller volume of distribution and shorter terminal half-life in rats than the previous leading CRF antagonists such as 1 ($V_d = 105$ L/kg, $t_{1/2} = 51$ h)⁹ and 4 (DMP696, $V_d = 22$ L/kg, $t_{1/2} = 16$ h).⁷ In light of these results, **16g** was further evaluated in vivo.

The in vivo functional antagonism of **16g** was determined using the CRF-induced ACTH release assay in normal rats. As shown in Figure 3, intravenous CRF (0.3 nmol/kg) administration in rats produced a robust increase in plasma levels of ACTH (p < 0.0007).




Figure 3. Dose-dependent effects of **16g** on CRF-induced ACTH release 10 min following CRF administration: (*) p < 0.0007 vs 10 mL/kg 5% D-mannitol (w/v) in water (Veh); (**) p < 0.002 vs CRF.

Compound **16g** significantly attenuated this effect in a dose-dependent manner with statistically significant reductions observed at the 10 and 30 mg/kg doses (p < 0.002 vs CRF). The observed attenuation of ACTH was 86% at the 30 mg/kg dose.

In conclusion, we have shown that tricyclic imidazo-[4,5-b]pyridin-2-one compounds are potent CRF₁ antagonists. The antagonistic activity of these compounds was demonstrated by their high affinities in binding to the CRF₁ receptor and inhibition of CRF-stimulated cAMP production. A representative from this series, 16g, possessed acceptable physicochemical properties for use as a central nervous system agent, showed a good overall in vitro profile, and had appropriate pharmacokinetics (especially favorably small volume of distribution) in rats. 16g not only inhibited CRFstimulated ACTH release in vitro but also dosedependently attenuated the elevation in plasma ACTH levels induced by CRF in rats in vivo. These results confirmed that 16g is a functional CRF_1 antagonist with improved physicochemical properties and a good pharmacokinetics profile. Further evaluation of 16g will be reported in due course.

Supporting Information Available: Experimental procedures for the synthesis and characterization of representative compounds, experimental details of the binding and functional assays, and X-ray structure for **16g**. This material is available free of charge via the Internet at http://pubs.acs.org.

References

- De Souza, E. B.; Grigoriadis, D. E. In Psychopharmacology: The Fourth Generation of Progress; Bloom, F. E., Kupfer, D. J., Eds.; Raven: New York, 1995; pp 505-517.
- (2) Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999, 33, 181-214.

- (3) O'Bien, D.; Skelton, K. H.; Owen, M. J.; Nemeroff, C. B. Are CRF receptor antagonists potential antidepressants? *Hum. Psycho-pharmacol. Clin. Exp.* 2001, 16, 81–87.
- (4) Schulz, D. W.; Mansbach, R. S.; Sprouse, J.; Braselton, J. P.; Collins, J.; Corman, M.; Dunaiskis, A.; Faraci, S.; Schmidt, A. W.; Seeger, T.; Seymour, P.; Tingley, F. D., III.; Winston, E. N.; Chen, Y.; Heym, J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. *Proc. Natl. Acad. Sci. U.S.A.* 1996, 93, 10477-10482.
- (5) Webster, E. L.; Lewis, D. B.; Torpy, D. J.; Zachman, E. K.; Rice, K. C.; Chrousos, G. P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. *Endocrinology* **1996**, *137*, 5747–5750.
- (6) Chen, C.; Dagnino, R., Jr.; De Souza, E. B.; Grigoriadis, D. E.; Huang, C. Q.; Kim, K. I.; Liu, Z.; Moran, T.; Webb, T. R.; Whitten, J. P.; Xie, Y. F.; McCarthy, J. R. Design and synthesis of a series of non-peptide high-affinity human corticotropin releasing factor 1 receptor antagonists. *J. Med. Chem.* **1996**, *39*, 4358-4360.
- (7) He, L.; Gilligan, P. J.; Zaczek, R.; Fitzgerald, L. W.; McElroy, J.; Shen, H.-S. L.; Saye, J. A.; Kalin, N. H.; Shelton, S.; Christ, D.; Trainor, G.; Hartig, P. 4-(1,3-Dimethoxyprop-2-ylamino)-2, 7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF1 receptor antagonist. J. Med. Chem. 2000, 43, 449-456.
- (8) Hsin, L.-W.; Tian, X.; Webster, E. L.; Coop, A.; Caldwell, T. M.; Jacobson, A. E.; Chrousos, G. P.; Gold, P. W.; Habib, K. E.; Ayala, A.; Eckelman, W. C.; Contoreggi, C.; Rice, K. C. CRHR1 receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. *Bioorg. Med. Chem.* **2002**, *10*, 175-183.
- (9) Keller, C.; Bruelisauer, A.; Lemaire, M.; Enz, A. Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. *Drug Metab. Dispos.* **2002**, *30*, 173–176.
- (10) Chen, C.; Wilcoxen, K. M.; Huang, C. Q.; Xie, Y. F.; McCarthy, J. R.; Webb, T. R.; Zhu, Y.-F.; Saunders, J.; Liu, X. J.; Chen, T.-K.; Bozigian, H.; Grigoriadis, D. E. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo-[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropinreleasing factor receptor antagonists. J. Med. Chem. 2004, 47, 4787-4798.
- (11) Gross, R. S.; Guo, Z.; Dyck, B.; Coon, T.; Huang, C. Q.; Lowe, R. F.; Marinkovic, D.; Moorjani, M.; Nelson, J.; Zamani-Kord, S.; Grigoriadis, D. E.; Hoare, S. R.; Crowe, P. D.; Bu, J. H.; Haddach, M.; McCarthy, J.; Saunders, J.; Sullivan, R.; Williams, J. P. Design and synthesis of tricyclic corticotropin-releasing factor-1 (CRF₁) antagonists. J. Med. Chem., in press.
- (12) Beck, J. P.; Arvanitis, A. G.; Curry, M. A.; Rescinito, J. T.; F., Fitzgerald, L. W.; Gilligan, P. J.; Zaczek, R.; Trainor, G. L. Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 967–972.
- (13) The crystal structure of 16g was determined and is shown in Figure 4 of Supporting Information.
- (14) De Souza, E. B. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J. Neurosci. 1987, 7, 88–100.
- (15) Grigoriadis, D. E.; Liu, X. J.; Vaughn, J.; Palmer, S. F.; True, C. D.; Vale, W. W.; Ling, N.; De Souza, E. B. ¹²⁵I-Tyrosauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor_{2a} receptors. *Mol. Pharmacol.* **1996**, *50*, 679–586.
- (16) Battaglia, G.; Webster, E. L.; De Souza, E. B. Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system. *Synapse* 1987, 1, 572–581.

JM050384+